Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
AssigneeJuno Therapeutics, Inc.
InventorsSusan Byrne, Richard Sullivan, Francois Vigneault
Life of this patent
Estimating the term…
Loading patent…
AssigneeJuno Therapeutics, Inc.
InventorsSusan Byrne, Richard Sullivan, Francois Vigneault
Estimating the term…
Provided are CCT5-binding molecules, including anti-CCT5 antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and conjugates comprising the anti-CCT5 binding molecules such as immunoconjugates and antibody-drug conjugates, and chimeric receptors comprising the anti-CCT5 binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-CCT5 antibodies or antigen-binding fragments thereof specifically bind to CCT5. Also provided are genetically engineered cells expressing the CARs or CCT5-binding molecules and uses thereof such as in adoptive cell therapy.
An antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment binds to a peptide sequence comprising the sequence TSVEDYKA (SEQ ID NO:70), SSVEAFKR (SEQ ID NO:71) or DSVEAIKA (SEQ ID NO:72), and wherein the antibody or antigen-binding fragment comprises
An antibody or antigen-binding fragment thereof that specifically binds to a chaperonin containing TCP1 subunit 5 (CCT5) protein comprising:
An antibody or antigen-binding fragment thereof that specifically binds to a chaperonin containing TCP1 subunit 5 (CCT5) protein, wherein the antibody or antigen-binding fragment comprises:
Dependencies are inferred from the claim text.